An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
Ferenc G Rick,1 Norman L Block,1–3 Andrew V Schally1–31Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, 2Department of Pathology, University of Miami, Miller School of Medicine,...
Main Authors: | Rick FG, Block NL, Schally AV |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-04-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/an-update-on-the-use-of-degarelix-in-the-treatment-of-advanced-hormone-a12785 |
Similar Items
-
Experience with degarelix in the treatment of prostate cancer
by: Neal D. Shore
Published: (2013-02-01) -
Pharmacoeconomic study of the degarelix drug use for treatment of hormone-dependent prostate cancer compared to gonadotropin-releasing hormone analogs
by: A. G. Tolkushin, et al.
Published: (2018-04-01) -
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer
by: Chiara Melloni, MD, MHS, et al.
Published: (2020-03-01) -
Evaluation of degarelix in the management of prostate cancer
by: Hendrik Van Poppel
Published: (2010-01-01) -
Degarelix and its therapeutic potential in the treatment of prostate cancer
by: Christian Doehn, et al.
Published: (2009-05-01)